Silodosin

證據等級: L5

預測適應症: 6 個

Silodosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Silodosin is a highly selective alpha-1A adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH) by relaxing prostatic and bladder-neck smooth muscle. The TxGNN model predicts a possible link to Ambras type hypertrichosis universalis congenita, a rare congenital hair-overgrowth syndrome, but this prediction is currently supported by 0 clinical trials and 0 publications.

Quick Overview

Item	Content
Original Indication	Benign Prostatic Hyperplasia (BPH)
Predicted New Indication	Ambras type hypertrichosis universalis congenita
TxGNN Prediction Score	99.99% (global rank 418)
Evidence Level	L5
Taiwan Market Status	未上市 (Not Marketed)
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data (DrugBank MOA field) is currently unavailable for this drug. Based on the pharmacological information available in this evidence pack, silodosin is a highly selective alpha-1A adrenergic receptor antagonist, used clinically to relax smooth muscle in the prostate and bladder neck for BPH symptom relief.

There is no known pharmacological or physiological pathway connecting alpha-1A adrenergic antagonism to Ambras type hypertrichosis, a rare genetic disorder typically associated with 8q chromosomal rearrangements affecting hair follicle development. No mechanistic, clinical, or literature evidence in this evidence pack supports a causal or therapeutic relationship between the two conditions.

Given the absence of any supporting trials or publications, and the biological implausibility of the mechanism, this prediction is most consistent with knowledge-graph embedding noise rather than a genuine pharmacological signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

No license records are currently available — silodosin is listed as not marketed (未上市) in Taiwan, with 0 registered licenses in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA warning/contraindication data and DDI data were both flagged as data gaps in this evidence pack — TFDA label warnings/contraindications is a Blocking gap that prevents any S1 safety pre-assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN similarity score, the predicted indication has no supporting clinical trials, no supporting literature, and no plausible mechanistic link to the drug’s known pharmacology. This pattern also holds for the other top-ranked candidates in this evidence pack (hypertrichosis, odontal/periodontal malformation syndrome — literature matched appears to be an entity-mismatch on unrelated periodontitis research, Dandy-Walker malformation, genetic hair shaft abnormality, familial trichomegaly), none of which show credible mechanistic or evidentiary support. This indication should not proceed past S0 without independent validation.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — currently a Blocking data gap
Confirmed DrugBank MOA record for silodosin
Preclinical or mechanistic studies specifically linking alpha-1A adrenergic antagonism to hair follicle/hypertrichosis biology
Re-validation of the TxGNN prediction to rule out knowledge-graph embedding artifacts, given the biological implausibility and complete absence of corroborating evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.